Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has reported that a new study, which used Magnetic Resonance Imaging (MRI) technology reveals that taking alli (orlistat 60mg) while following a reduced calorie, lower-fat diet can lead to a reduction not only in weight but also in dangerous visceral fat.
Subscribe to our email newsletter
The research, carried out over three months at Europe’s largest imaging centre, illustrates the changes taking place inside someone’s body as they take alli plus diet. It supports that overweight adults (with a BMI of 28 or over) using alli in conjunction with a reduced calorie, lower-fat diet can not only lose 5% of their body weight but also 10% of dangerous visceral fat versus baseline.
Results also showed that at week 12 waist circumference, the practical marker for visceral fat, could also be reduced. These findings, when considered with existing data, suggest that adding alli to diet not only helps overweight adults lose 50% more weight than dieting alone, but this weight loss also helps improve health. For every two pounds they lose through their own efforts, adding alli can help them lose one more.
Additional data presented show that alli was effective than placebo in reducing waist size, with an average loss of 4.5cm (1.8 inches), over 6 months of treatment. Levels of total and LDL cholesterol were also lower in those people taking alli compared with placebo.
The company said that alli is a non-prescription weight loss aid, containing orlistat 60mg, for overweight adults (18 years or over) with a body mass index (BMI) of 28 or more. It should be used with a reduced calorie, lower fat diet. Always read the label.